Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
1.450
-0.040 (-2.68%)
At close: Apr 28, 2026, 4:00 PM EDT
1.300
-0.150 (-10.34%)
After-hours: Apr 28, 2026, 6:21 PM EDT
Rein Therapeutics Employees
Rein Therapeutics had 10 employees as of December 31, 2025. The number of employees decreased by 1 or -9.09% compared to the previous year.
Employees
10
Change (1Y)
-1
Growth (1Y)
-9.09%
Revenue / Employee
n/a
Profits / Employee
-$4,987,100
Market Cap
40.66M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Xilio Therapeutics | 76 |
| Mereo BioPharma Group | 39 |
| Plus Therapeutics | 28 |
| PDS Biotechnology | 24 |
| Atossa Therapeutics | 16 |
| Rallybio | 14 |
| Nutriband | 13 |
| Hyperion DeFi | 9 |
RNTX News
- 6 months ago - Why Is Rein Therapeutics Stock Trading Higher On Monday? - Benzinga
- 7 months ago - Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 7 months ago - Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 9 months ago - Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - GlobeNewsWire
- 9 months ago - Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025 - GlobeNewsWire
- 9 months ago - Rein Therapeutics Transcript: AGM 2025 - Transcripts
- 11 months ago - Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders - PRNewsWire
- 11 months ago - US FDA puts on hold Rein Therapeutics' lung disease drug trial - Reuters